| 1 | 1394219 | Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. | Cancer Res | 1992 Nov 1 |
1 |
| 2 | 8273115 | Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione). | Steroids | 1993 Nov |
1 |
| 3 | 11250604 | [Preclinical evaluation of aromatase inhibitors antitumor activity]. | Bull Cancer | 2000 Dec |
1 |
| 4 | 11550075 | Aromatase, aromatase inhibitors, and breast cancer. | Am J Ther | 2001 Sep-Oct |
2 |
| 5 | 11850211 | Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. | J Steroid Biochem Mol Biol | 2001 Dec |
2 |
| 6 | 11916226 | Are differences in the available aromatase inhibitors and inactivators significant? | Clin Cancer Res | 2001 Dec |
4 |
| 7 | 12113240 | Aromatase inhibitors in breast cancer therapy. | Expert Rev Anticancer Ther | 2002 Apr |
2 |
| 8 | 12402060 | The evolving role of aromatase inhibitors in breast cancer. | Int J Clin Oncol | 2002 Oct |
4 |
| 9 | 12455303 | Exemestane: treatment of breast cancer with selective inactivation of aromatase. | Am J Health Syst Pharm | 2002 Nov 15 |
1 |
| 10 | 12684675 | Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? | Int J Oncol | 2003 May |
1 |
| 11 | 12722879 | Aromatase inhibitors for treatment of postmenopausal patients with breast cancer. | Expert Rev Anticancer Ther | 2003 Apr |
2 |
| 12 | 14513436 | Aromatase inhibitors in early breast cancer treatment. | Semin Oncol | 2003 Aug |
1 |
| 13 | 14623539 | An integrated view of aromatase and its inhibition. | J Steroid Biochem Mol Biol | 2003 Sep |
1 |
| 14 | 15083379 | Aromatase inhibitors: new endocrine treatment of breast cancer. | Semin Reprod Med | 2004 Feb |
2 |
| 15 | 15125996 | A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction. | Toxicology | 2004 Jun 1 |
1 |
| 16 | 15150604 | Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? | Br J Cancer | 2004 May 4 |
1 |
| 17 | 15358790 | Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. | J Biol Chem | 2004 Nov 12 |
2 |
| 18 | 15476902 | Role of aromatase inhibitors in the treatment of breast cancer. | Clin Ther | 2004 Aug |
1 |
| 19 | 15719595 | Aromatase inhibitors in advanced breast cancer. | Semin Oncol | 2004 Dec |
1 |
| 20 | 15719596 | Aromatase inhibitors in early breast cancer therapy. | Semin Oncol | 2004 Dec |
1 |
| 21 | 15723135 | Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy. | Bull Exp Biol Med | 2004 Nov |
1 |
| 22 | 15748828 | Aromatase expression in ovarian epithelial cancers. | J Steroid Biochem Mol Biol | 2005 Jan |
2 |
| 23 | 15814851 | Aromatase inhibitors in the treatment of breast cancer. | Endocr Rev | 2005 May |
1 |
| 24 | 15909811 | [Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma]. | Vopr Onkol | 2005 |
1 |
| 25 | 16054421 | New approaches to reverse resistance to hormonal therapy in human breast cancer. | Drug Resist Updat | 2005 Aug |
1 |
| 26 | 16322257 | Human aromatase: gene resequencing and functional genomics. | Cancer Res | 2005 Dec 1 |
1 |
| 27 | 16904960 | Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. | Bone | 2007 Jan |
1 |
| 28 | 16950593 | Metastatic breast cancer: an updating. | Biomed Pharmacother | 2006 Nov |
1 |
| 29 | 17066438 | 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. | Int J Cancer | 2007 Jan 15 |
2 |
| 30 | 17079446 | Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. | Cancer Res | 2006 Nov 1 |
8 |
| 31 | 17150002 | Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies. | Expert Opin Pharmacother | 2006 Dec |
1 |
| 32 | 17695434 | Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. | Anticancer Res | 2007 Jul-Aug |
2 |
| 33 | 17904790 | Aromatase inhibitor and bone. | Biomed Pharmacother | 2007 Oct |
1 |
| 34 | 17989318 | Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. | Mol Cancer Ther | 2007 Nov |
2 |
| 35 | 18043897 | Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). | Breast Cancer Res Treat | 2008 Jan |
3 |
| 36 | 18158620 | Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). | Breast Cancer Res Treat | 2008 Nov |
3 |
| 37 | 18194278 | NSAIDs and breast cancer: a possible prevention and treatment strategy. | Int J Clin Pract | 2008 Mar |
1 |
| 38 | 18256205 | CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma. | Drug Metab Dispos | 2008 May |
1 |
| 39 | 18282367 | Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors. | Clin Breast Cancer | 2007 Dec |
1 |
| 40 | 18367396 | Aromatase inhibitors in early breast-cancer treatment: The story so far. | Breast | 2008 Apr |
1 |
| 41 | 18381432 | The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. | Cancer Res | 2008 Apr 1 |
10 |
| 42 | 18473177 | Exemestane loaded self-microemulsifying drug delivery system (SMEDDS): development and optimization. | AAPS PharmSciTech | 2008 |
1 |
| 43 | 18490163 | Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence? | Breast | 2008 Aug |
1 |
| 44 | 18677558 | Characterization of the weak estrogen receptor alpha agonistic activity of exemestane. | Breast Cancer Res Treat | 2009 Aug |
1 |
| 45 | 19046724 | The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. | Eur J Intern Med | 2008 Dec |
2 |
| 46 | 19250201 | Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators. | Ann N Y Acad Sci | 2009 Feb |
2 |
| 47 | 19281057 | Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. | Clin Interv Aging | 2008 |
1 |
| 48 | 19659610 | Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. | Cancer Sci | 2009 Nov |
3 |
| 49 | 19661043 | Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors. | Clin Breast Cancer | 2009 Aug |
1 |
| 50 | 19670731 | [Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma]. | Vopr Onkol | 2009 |
1 |